Breast cancer is on the rise across Asia, with more women contracting the disease than ever before.
Although pharmaceuticals are the main treatment route, medical devices are needed to fight the disease on a new level.
The need is growing for life-saving treatments.
Although the market is expected to experience strong growth, the quality of care is inconsistent.
With the exception of a few countries, Asia’s disease management industry is relatively unstructured.
While Western countries still have more medical device startups than the rest of the world, more new medtech startups are popping up in Asia than ever before.
The President’s actions (or distractions) may be detrimental to Western medical device companies.
With the increase of diabetes prevalence in Asia and the rise of Asia’s middle classes, the demand for newer and better treatments will provide opportunities for Western medtech companies.
As standalone software becomes increasingly sophisticated, a number of regulatory bodies have begun to draft separate guidelines to ensure quality control, expedite product approval, and improve patient access to new technologies.
Global sports medicine is predicted to grow to around $35 billion by 2022, with the Asian market growing at a compound annual growth rate of nearly 7 percent.